Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Oncology stories

Nov 13, 2026

FDA approves durvalumab plus enfortumab vedotin for muscle-invasive bladder cancer

The FDA approved AstraZeneca's durvalumab combined with enfortumab vedotin as neoadjuvant treatment followed by adjuvant durvalumab after radical cystectomy for muscle-invasive bladder cancer. The approval adds a new perioperative immunotherapy option for this high-risk cancer.

Nov 13, 2026·2 sources
00
Nov 7, 2026

T-Therapeutics raises $133M Series B for T-cell therapies in cancer and autoimmune disease

UK-based T-Therapeutics closed a $133 million Series B funding round led by Advent Life Sciences and British Business Bank to advance T-cell therapies targeting cancer and autoimmune diseases.

Nov 7, 2026·2 sources
00
Oct 30, 2026

Hiroshima University finds hyperactive YAP/TAZ proteins help cancer cells evade immune system

Researchers at Hiroshima University and international collaborators discovered that hyperactive YAP and TAZ proteins, which promote cancer, are associated with genomic instability that enables tumor cells to evade immune system detection and destruction.

Oct 30, 2026·2 sources
00
Oct 29, 2026

METTL13 enzyme found to fuel cancer growth by boosting KRAS protein production

Researchers at MD Anderson Cancer Center discovered that the METTL13 enzyme modifies translation machinery to selectively enhance production of cancer-driving proteins like KRAS, offering a potential new therapeutic target upstream of existing KRAS-targeted drugs that face resistance issues.

Oct 29, 2026·3 sources
00

Northwestern Medicine develops liquid biopsy blood test for small cell lung cancer

Northwestern Medicine scientists have demonstrated a novel liquid biopsy technique that can measure cancer burden and reveal molecular characteristics of small cell lung cancer, according to a study published in the Journal of Clinical Investigation. The approach could eventually allow for better tracking and monitoring of this aggressive cancer type.

Oct 29, 2026·2 sources
00

Roswell Park researchers identify timing window for immunotherapy in prostate cancer treatment

Researchers at Roswell Park Comprehensive Cancer Center have discovered that hormone-blocking therapies commonly used to treat prostate cancer temporarily activate the body's immune response, revealing a critical window for boosting immunotherapy effectiveness.

Oct 29, 2026·1 source
00
Oct 27, 2026

Bevacizumab and pazopanib combination extends survival in kidney cancer trial

A phase 1/2 trial led by Roswell Park Comprehensive Cancer Center found that combining bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with metastatic clear-cell renal cell carcinoma, the most common type of kidney cancer. The study established a safe dosing regimen and demonstrated promising antitumor activity in treatment-naive patients.

Oct 27, 2026·2 sources
00
Oct 26, 2026

GSK to nearly double cancer drugs in clinical trials by 2027

GSK expects to nearly double the number of cancer medicines it is testing in clinical trials next year, according to a Wall Street Journal interview with a company scientist. The expansion follows a dealmaking spree as the British drugmaker accelerates its return to oncology.

Oct 26, 2026·5 sources
00

FDA expands talazoparib approval for metastatic prostate cancer

The FDA approved the PARP inhibitor talazoparib in combination with enzalutamide for treatment of patients with metastatic androgen pathway modulation-naive or -sensitive prostate cancer.

Oct 26, 2026·2 sources
00

Fewer US men diagnosed with low-risk prostate cancer as surveillance replaces treatment

An analysis published in CANCER reveals a broad shift away from overtreatment of low-risk prostate cancer in the United States, with more men choosing surveillance over immediate treatment in response to concerns about overdiagnosis and overtreatment.

Oct 26, 2026·1 source
00
Oct 24, 2026

Amgen's Imdelltra combo cuts death risk 58% in small cell lung cancer trial

Amgen's Imdelltra combined with AstraZeneca's Imfinzi reduced the risk of death by 58% compared to Imfinzi alone in patients with extensive-stage small cell lung cancer, adding eight months of life in a late-stage trial presented at ESMO.

Oct 24, 2026·3 sources
00

Nearly 30% of advanced melanoma patients achieve complete tumor disappearance with lifileucel TIL therapy plus pembrolizumab

Clinical trial results show 29.2% of patients with advanced melanoma experienced complete tumor disappearance on scans after receiving lifileucel TIL therapy combined with pembrolizumab immune checkpoint inhibitor as first-line treatment. The IOV-COM-202 trial demonstrates significant efficacy for this combination immunotherapy approach.

Oct 24, 2026·1 source
00
Oct 23, 2026

Standard kidney function tests underestimate chronic kidney disease in cancer patients, study finds

New research presented at ASN Kidney Week 2026 reveals that commonly used measures of kidney function underestimate the prevalence of chronic kidney disease in patients with cancer. The study compared measured glomerular filtration in 1,200 adults with solid tumors.

Oct 23, 2026·2 sources
00

Real-world study confirms Lu-PSMA-617 benefits for metastatic prostate cancer patients

Results from France's early-access program demonstrate that PSMA-targeted radiopharmaceutical therapy Lu-PSMA-617 is safe and effective for patients with metastatic castration-resistant prostate cancer in routine clinical practice, confirming findings from controlled trials.

Oct 23, 2026·4 sources
00

Bristol Myers Squibb and SystImmune breast cancer drug reduces disease progression risk by 59% in phase 3 trial

Bristol Myers Squibb and partner SystImmune announced that their experimental breast cancer treatment izalontamab brengitecan reduced the risk of disease progression or death by 59% compared to standard chemotherapy in patients with advanced HR+/HER2- breast cancer in the phase 3 PANKU-Breast01 study. The late-breaking results are being presented at ESMO 2026.

Oct 23, 2026·4 sources
00

Novartis breast cancer drug Kisqali cuts death risk by 19% after six years in early-stage trial

Novartis reported that its drug Kisqali helped extend survival for women with high-risk, early-stage breast cancer, cutting their risk of death by 19% after six years in trial data.

Oct 23, 2026·2 sources
00

Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

Tango Therapeutics reported an 82% tumor response rate in a clinical trial combining targeted drugs for advanced pancreatic cancer, presented at ESMO congress.

Oct 23, 2026·2 sources
00

Roche licenses Zymeworks' experimental lung cancer drug ZW209 in deal worth up to $813 million

Roche has entered into a global license and collaboration agreement with Zymeworks for ZW209, a trispecific T cell engager targeting DLL3 for lung cancer treatment. The deal includes $55 million upfront, up to $718 million in milestone payments, and tiered royalties on future sales.

Oct 23, 2026·5 sources
00

Johnson & Johnson prostate cancer drug JNJ-6143 shows tumor shrinkage in early-stage trial

Johnson & Johnson reported promising results from an early-stage clinical trial of its experimental oral prostate cancer treatment JNJ-6143, with 77% of patients with advanced prostate cancer experiencing significant drops in PSA levels after treatment. The trial involved patients who had undergone multiple prior treatments.

Oct 23, 2026·4 sources
00

Diagnostic test could help doctors refine prostate cancer treatment with abiraterone

A novel diagnostic test could enable doctors to identify which prostate cancer patients would benefit from more intensive treatment with drugs like abiraterone, while sparing others from unnecessary side effects. The test aims to address the challenge of tailoring treatment for prostate cancer, which affects over 1 million men worldwide and behaves differently in each patient.

Oct 23, 2026·5 sources
00

Researchers discover how chronic lymphocytic leukemia cells evade treatment by switching survival signals

A new study published in Blood Journal reveals that chronic lymphocytic leukemia (CLL) cells can switch between different survival signals to evade treatment, helping explain why therapies work for some patients but develop resistance in others. The research identifies how cancer cells alternate between low and high basal signaling states through TLR9 activation.

Oct 23, 2026·3 sources
00

RCSI study identifies new treatment targets for most common type of colorectal cancer

An international research team led by RCSI University of Medicine and Health Sciences and The Institute of Cancer Research, London has identified potential new treatment approaches for microsatellite-stable colorectal cancer, the most common type in Ireland. The study provides a roadmap for repurposing existing drugs to treat this cancer subtype.

Oct 23, 2026·3 sources
00

New analysis shows daraxonrasib survival benefits across patient groups in advanced pancreatic cancer

A new analysis of a phase 3 clinical trial presented at ESMO 2026 found that daraxonrasib, a recently approved targeted therapy, improved survival compared with standard chemotherapy across multiple patient groups with advanced pancreatic cancer. The drug represents the biggest advance in decades against the notoriously hard-to-treat disease.

Oct 23, 2026·4 sources
00
Oct 22, 2026

Moderna and Merck melanoma vaccine cuts death or recurrence risk by 42% in phase 3 trial

The mRNA-based personalized cancer vaccine combined with Keytruda reduced the risk of melanoma death or recurrence by 42% in a late-stage trial, though leaked data triggered a sell-off in Moderna shares despite meeting expectations.

Oct 22, 2026·5 sources
00

Earlier survivorship care linked to lower risk of head and neck cancer recurrence and death

A University of Pittsburgh study published in JAMA Otolaryngology–Head & Neck Surgery found that head and neck cancer patients who participated in multidisciplinary survivorship clinics earlier experienced better survival rates and lower cancer recurrence compared to those who began survivorship care later.

Oct 22, 2026·2 sources
00
Oct 20, 2026

Dana-Farber and Beth Israel begin construction of $1.68 billion cancer hospital

Dana-Farber Cancer Institute and Beth Israel Lahey Health are starting construction on a $1.68 billion cancer hospital in Boston, marking a new phase in their competition with Mass General Brigham.

Oct 20, 2026·2 sources
00
Oct 19, 2026

Mass General Brigham AI tool predicts cancer survival from facial photographs

Researchers at Mass General Brigham have developed an AI system called FAHR-Face that can predict cancer patients' survival chances using a single photograph of their face. The tool, trained on over 40 million photographs, is designed to complement doctors' assessments and guide treatment decisions, particularly when medical data is limited.

Oct 19, 2026·14 sources
00

Peter Mac scientists develop CRISPR method to target gene fusions in one in five cancers

Scientists at Peter MacCallum Cancer Centre have developed a new CRISPR approach using PspCas13b nuclease to precisely target abnormal gene fusions, which occur in approximately 20% of cancers. The technique targets the unique molecular fingerprint created when two genes fuse together, potentially offering a new personalized treatment strategy.

Oct 19, 2026·1 source
00
Oct 2, 2026

Scientists discover how to control MYC cancer gene amplification

Researchers at Fox Chase Cancer Center have uncovered the epigenetic mechanisms that control MYC gene amplification, offering potential new approaches to targeting this cancer-driving gene found in 70 percent of cancers. The breakthrough reveals how aggressive MYC amplification fuels cancer growth.

Oct 2, 2026·3 sources
00
Sep 28, 2026

Medicare drug price negotiations strain oncology practices despite patient cost relief

The Inflation Reduction Act's Medicare out-of-pocket cap is reducing costs for cancer patients, but community oncology leaders warn that negotiated drug price cuts are creating financial pressures on medical practices.

Sep 28, 2026·2 sources
00
Sep 12, 2026

FDA expands approval for sevabertinib to frontline treatment of HER2-mutant advanced NSCLC

The US Food and Drug Administration has granted expanded accelerated approval for sevabertinib as a frontline treatment option for patients with HER2-mutant advanced non-small cell lung cancer, with nursing management focusing on diarrhea monitoring.

Sep 12, 2026·1 source
00
Aug 10, 2026

Sobi and Innate Pharma Form $580M Partnership to Advance Lacutamab to Phase 3 for Rare Skin Cancer

Swedish Orphan Biovitrum (Sobi) and Innate Pharma announced a strategic partnership worth up to $580 million, with $75 million upfront, to advance lacutamab into the TELLOMAK-3 Phase 3 confirmatory trial for cutaneous T-cell lymphoma, specifically Sézary syndrome. Innate Pharma also appointed Markus Jensen as Chief Medical Officer.

Aug 10, 2026·9 sources
00
Aug 9, 2026

Maura L. Gillison, who linked throat cancers to HPV, dies at 61

Dr. Maura L. Gillison, the researcher who discovered the connection between human papillomavirus (HPV) and throat cancers, has died at age 61. Her groundbreaking work transformed understanding of oropharyngeal cancer and influenced prevention strategies.

Aug 9, 2026·1 source
00
Aug 4, 2026

Pathos AI Signs Two Major Breast Cancer Drug Licensing Deals Worth Over $2B, Plans $3B Series E

Pathos AI announced two significant licensing agreements for breast cancer treatments: a $2.2 billion deal with China's Alphamab Oncology for bispecific ADC JSKN016 targeting triple-negative breast cancer, and a co-exclusive agreement with AstraZeneca for ERα degrader AZD4241 for ER-positive breast cancer. The company is reportedly planning to raise a Series E round at a $3 billion valuation.

Aug 4, 2026
00
Jul 28, 2026

University researchers develop new human tissue model to study glioblastoma infiltration

Scientists at the University have created a new human tissue model that tracks how glioblastoma, an aggressive brain tumor, infiltrates surrounding brain tissue. The research aims to address the challenge of tumor recurrence after surgery, when remaining cells cause the cancer to return.

Jul 28, 2026·1 source
00

GSK partner Hansoh Pharmaceutical's bone cancer drug meets primary endpoint in second Phase III trial in China

Hansoh Pharmaceutical announced positive results from the ARTEMIS-011 Phase III trial in China, with its experimental drug Ris-Rez meeting the primary endpoint of progression-free survival in relapsed bone cancer patients. This marks the second Phase III success for the drug, strengthening GSK's oncology portfolio through its licensing partnership with the Chinese biotech.

Jul 28, 2026·3 sources
00
Jul 27, 2026

AstraZeneca reports mixed late-stage trial results with Ultomiris failure and Claudin 18.2 ADC success

AstraZeneca announced Monday that its rare disease drug Ultomiris failed a late-stage trial for blood vessel complications following stem cell transplants, while a separate trial of its Claudin 18.2-targeting antibody-drug conjugate in stomach cancer succeeded. The Ultomiris setback adds to concerns about the drugmaker's pipeline following a series of setbacks this year.

Jul 27, 2026
00

AstraZeneca's Sonesitatug Vedotin Shows Significant Survival Improvement in Phase III Gastric Cancer Trial

Phase III CLARITY-Gastric01 trial results showed sonesitatug vedotin (Sone-Ve) achieved statistically significant overall survival improvement in CLDN18.2-positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma patients in second-line and later settings, meeting its dual primary and key secondary endpoints.

Jul 27, 2026·4 sources
00
Jul 14, 2026

FDA Approves Celcuity's Revtorpyk (Gedatolisib) for Advanced Breast Cancer

The U.S. Food and Drug Administration has approved Revtorpyk (gedatolisib), Celcuity's first drug to reach market, for treating hormone receptor positive, HER2 negative advanced breast cancer. The approval sent the company's shares up 7% in extended trading.

Jul 14, 2026·4 sources
00
Jul 2, 2026

Roche's divarasib outperforms Amgen and Bristol Myers Squibb drugs in Phase 3 lung cancer trial

Roche announced positive results from a head-to-head Phase 3 trial showing its KRAS G12C inhibitor divarasib demonstrated superior efficacy compared to competing treatments from Amgen and Bristol Myers Squibb in patients with KRAS-driven lung cancer.

Jul 2, 2026·4 sources
00
Jun 30, 2026

BeOne Medicines' Brukinsa Meets Primary Endpoint in Phase 3 Frontline Mantle Cell Lymphoma Trial

BeOne Medicines announced positive Phase 3 results from the MANGROVE trial, showing Brukinsa plus rituximab reduced the risk of disease progression or death by 43% compared to bendamustine plus rituximab in frontline mantle cell lymphoma patients. The combination represents a potential chemotherapy-free treatment option.

Jun 30, 2026·4 sources
00
Jun 29, 2026

AbbVie and Genmab's Epkinly Combination Meets Primary Endpoint in Phase 3 Trial for Relapsed/Refractory DLBCL

The EPCORE DLBCL-4 Phase 3 trial showed that epcoritamab (Epkinly) combined with lenalidomide significantly improved progression-free survival compared to R-GemOx chemotherapy in adults with relapsed or refractory diffuse large B-cell lymphoma who received at least one prior line of therapy. The results bring the bispecific antibody closer to a potential label expansion.

Jun 29, 2026·6 sources
00
Jun 24, 2026

FDA approves Trodelvy for first-line triple-negative breast cancer

The FDA approved sacituzumab govitecan-hziy (Trodelvy) on June 24, 2026, for two indications in adults with triple-negative breast cancer: as monotherapy and in combination with pembrolizumab (Keytruda) for first-line treatment of advanced disease, offering new options beyond standard chemotherapy.

Jun 24, 2026·3 sources
00
Jun 22, 2026

China Approves World's First CAR-T Therapy for Solid Tumors to Treat Advanced Gastric Cancer

China's National Medical Products Administration has approved satricabtagene autoleucel (Satri-cel, CT041, Kaileimei®), marking the first CAR-T cell therapy approved globally for treating solid tumors, specifically for CLDN18.2-positive, HER2-negative advanced gastric and gastroesophageal junction adenocarcinoma.

Jun 22, 2026·4 sources
00
Jun 12, 2026

FDA Approves Belzutifan Plus Pembrolizumab as Adjuvant Therapy for Clear Cell Renal Cell Carcinoma

The FDA has approved the combination of belzutifan (Welireg) and pembrolizumab (Keytruda) as adjuvant treatment for patients with clear cell renal cell carcinoma at high risk of recurrence following nephrectomy, based on data from the phase 3 LITESPARK-022 trial.

Jun 12, 2026·3 sources
00
Jun 1, 2026

Moderna's personalized mRNA melanoma vaccine cuts cancer recurrence risk by half in five-year trial results

New clinical trial results presented at the American Society of Clinical Oncology show that Moderna's experimental personalized mRNA vaccine, combined with immunotherapy, significantly reduced the risk of deadly melanoma returning after five years. The vaccine is custom-made for each patient based on their specific tumor.

Jun 1, 2026·4 sources
00
May 30, 2026

Multi-fraction stereotactic radiation improves local control for large brain metastases in phase 3 trial

The first randomized phase 3 trial comparing radiation schedules found that delivering stereotactic radiation over three to five sessions after surgery significantly improved local control and reduced cancer recurrence at the surgical site for patients with large, resected brain metastases compared with single-fraction treatment.

May 30, 2026·3 sources
00

Top claims

  • ▪In the phase 3 VOLGA trial, neoadjuvant durvalumab plus enfortumab vedotin achieved an estimated 24-month event-free survival rate of 63.5% compared to 45.1% with radical cystectomy alone
  • ▪In the phase 3 VOLGA trial, grade 3 or higher adverse events occurred in 71.1% of muscle-invasive bladder cancer patients receiving durvalumab plus enfortumab vedotin compared to 50.2% undergoing surgery alone
  • ▪In the phase 3 VOLGA trial, pathologic complete response by local review was achieved in 45.1% of patients receiving durvalumab plus enfortumab vedotin versus 9.6% with radical cystectomy alone

Subtopics

Cancer & Oncology46Cancer treatment28Drug Policy, Pricing & Approval25Clinical trials22Cancer treatment breakthroughs20Drug Approval and Clinical Trials14Cancer research13Cancer Treatment & Therapies11Cancer10Cancer immunotherapy10Cancer Types9Drug development7Targeted cancer therapy7Cancer and Cancer Treatment6Clinical Trial Design & Evaluation6Immunotherapy6FDA drug approval5Biomedical research4Personalized medicine4Pharma4Cancer diagnosis3Clinical evaluation3Clinical trial endpoints3Molecular biology3

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories